BACKGROUND: Data to standardize and harmonize the differences between cardiac troponin assays are needed to support their universal status in diagnosis of myocardial infarction. We characterized the variation between methods, the comparability of the 99th-percentile cutoff thresholds, and the occurrence of outliers in 4 cardiac troponin assays.
RESULTS:
The observed total variances between the 3 cardiac troponin I (cTnI) methods and between the cTnI and cardiac troponin T (cTnT) methods were larger than expected from the analytical imprecision (3.0%-3.7%). The between-method variations of 26% between cTnI assays and 127% between cTnI and cTnT assays were the dominant contributors to total variances. The misclassification of results according to the 99th percentile was 3%-4% between cTnI assays and 15%-17% between cTnI and cTnT. The Roche cTnT assay identified 49% more samples as positive than the Abbott cTnI. Outliers between methods were detected in 1 patient (0.06%) with Abbott, 8 (0.45%) with Beckman Coulter, 10 (0.56%) with Roche, and 3 (0.17%) with Siemens.
CONCLUSIONS:
The universal definition of myocardial infarction should not depend on the choice of analyte or analyzer, and the between-and within-method differences described here need to be considered in the application of cardiac troponin in this respect. The variation between methods that cannot be explained by analytical imprecision and the discordant classification of results according to the respective 99th percentiles should be addressed.
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The universal definition of myocardial infarction (MI) 3 is based on a rising and/or falling pattern of cardiac troponin with at least 1 result above the 99th percentile of a reference population (1 ) . This definition makes no distinction among different cardiac troponin I (cTnI) assays, or indeed between cTnI and cardiac troponin T (cTnT). Furthermore, the definition presupposes that application of the respective 99th percentiles would concordantly classify the same patient population regardless of which analytical platform is used. In view of the pivotal role that cardiac troponin plays in the management of patients with acute coronary syndromes, it is crucial that the analytical methods used for its measurement are precise and comparable. The imprecision and analytical sensitivity of the various cardiac troponin assays are well studied, and great effort has been made by the industry to improve these parameters. It is well documented that cardiac troponin assays lack standardization and harmonization, but data on the extent of this aspect are incomplete (2) (3) (4) (5) . Although method imprecision has a clearly stated target (CV of 10% at the 99th percentile), none exists for method standardization and/or harmonization. Statistics are needed to set quality targets for method harmonization and to measure the success of quality improvement initiatives.
We recently reported on the robustness of 3 contemporary cTnI assays and a cTnT assay by analyzing clinical samples in duplicate (6 ) . The aim of the current article was to compare and investigate the betweenmethod performance of these cardiac troponin assays to gain better insight into their commutability. We spe-cifically investigated the variance between methods, the classification of patient results relative to their respective 99th percentiles, and the occurrence of outliers between the respective methods.
Materials and Methods
The study population, quality control procedures, imprecision parameters, and identification of withinmethod outliers have been described in detail (6 ) . Serum cardiac troponin was measured on 4 contemporary analytical platforms: (a) Abbott Architect i2000SR analytical system with STAT Troponin-I reagent (Abbott Diagnostics); (b) Beckman Coulter Access2 analyzer with Enhanced AccuTnI reagent (reagent part no. A78803, Beckman Coulter Diagnostics); (c) Roche Cobas e601 with TroponinT high-sensitivity reagent (Roche Diagnostics); and (d) Siemens Advia Centaur XP with TnI-Ultra reagent (Siemens Healthcare Diagnostics). After exclusion of 33 samples where a withinmethod outlier was detected, 2358 samples with duplicate results were available for further analysis.
We used results above the respective 20% CV limits of quantification (LOQ 20% ) in the calculations of regressions and variances. To estimate the intercept and slope parameters, we applied Passing-Bablok regression to the log 10 (x ϩ 1)-transformed average duplicate troponin results for each sample to relate each of the other methods to Abbott, which was arbitrarily chosen as the reference method. The regression parameters were applied to each individual sample to produce an Abbott-equivalent result, which was back-transformed to the original scale before variance component estimations were performed.
Data were divided into 11 bins according to the Abbott cardiac troponin result as indicated in Table 1 . The components of variance were estimated separately for each bin with a balanced-data, 2-factor mixed effects model ANOVA procedure (7 ) . The detail of the model is further explained in the Data Supplement, which accompanies the online version of this article at http://www.clinchem.org/content/vol58/issue1. The total observed variance of the differences between 2 methods is equal to the within-method analytical variances plus the between-method analytical variance factors (8, 9 ) . To facilitate comparison across the measuring range, we expressed variances as the CV relative to the method pair mean value within the bin. A weighted mean of the CV across bins summarized the patterns for each pair of methods. To illustrate the magnitude of the observed variation between methods, we plotted the percentage differences between the standardized methods against the bin-specific mean value.
To investigate discordant classification according to the respective 99th-percentile decision limits of the untransformed data, the decision thresholds were iteratively adjusted relative to the Abbott. Marginal homogeneity at the 99th-percentile decision limits was tested by the McNemar procedure.
We identified outliers between methods by calculating z values from the differences between the mean results and the observed SD of the differences (SDd) between analyzers in each bin:
z Values exceeding 3.48 identified outliers at P ϭ 0.0005. We confirmed the outliers by visual inspection of scatterplots, and the probable source of error was identified by process of elimination. Samples identified as outliers between methods were tested for heterophile antibodies on serum aliquots stored at Ϫ80°C with a heterophilic antibody blocking technique (Scantibodies Laboratory).
As part of routine care, creatinine was measured with an isotope dilution-adjusted method (Beckman Coulter Unicel DxC800, Beckman Coulter Diagnostics), and estimated glomerular filtration rate (eGFR) was calculated with the Modification of Diet in Renal Disease 4-variable formula. The hemolytic index was recorded on samples where serum creatinine was measured with significant hemolysis of approximately 100 mg/dL, equivalent to a hemolytic index Ͼ2. Data analysis and statistical procedures were performed with SPSS v.17 software. Statistical testing was performed at the P Ͻ 0.05 significance level.
Results
A total of 2358 result pairs on 1773 individuals from the original study were available for further analysis, with eGFR results available on 2135 samples. The relationships between the cTnI methods were linear on log 10 (x ϩ 1)-transformed data, and the methods were highly correlated (Spearman Ͼ 0.98) (Fig. 1) . Beckman Coulter cTnI results were equivalent to Abbott's, with slope 0.988. Siemens cTnI results were systematically higher than Abbott's and required correction with a slope of 1.199 to give equivalent results. Roche cTnT results were systematically lower than Abbott's and required correction with slope 0.355. Roche cTnT results were well correlated with those of Abbott (Spearman Ͼ 0.89).
The total observed CVs for the differences (CVd observed ) between the 3 cTnI methods and between the cTnI and cTnT methods were partitioned into components of within-method analytical imprecision (CVd wm ) and between-method analytical variation (CVd bm ) ( Table 1 and Fig. 2 ). CVd wm values were con-sistently low at 3.0%-3.7%. The CVd bm values for the cTnI methods were relatively constant, with weighted averages of 21.8% to 29.7% compared to those of cTnT and the respective cTnI methods, 124.9% to 127.8%.
The agreement between methods in terms of classifying results around the respective 99th-percentile decision limits is summarized in Table 2 . The cTnI methods demonstrated good agreement (Cohen Ͼ 0.90), though the Siemens cTnI method classified a significantly greater proportion of results as positive (McNemar P Ͻ 0.001). The published Roche cTnT 99th percentile identified 47% (1107/2358) of samples in this study as positive compared to 32% (742/2358) with the Abbott cTnI, which translates into a 49% (365/ 742) higher positive rate with Roche. After iterative adjustment of the decision thresholds to achieve optimum classification relative to the Abbott cTnI, the Beckman Coulter cTnI remained at 0.040 g/L, the equivalent Roche cTnT decision threshold was 0.032 g/L, and the Siemens cTnI decision threshold was 0.046 g/L.
The effect of eGFR on cTnT relative to the Abbott cTnI is presented in Fig. 3 (similar data were obtained for the Beckman Coulter and Siemens cTnI methods; data not shown). An inverse relationship was demonstrated between eGFR and cTnT concentrations, with cTnT higher relative to cTnI when eGFR was increase in cTnT with decreased eGFR did not explain the discordant classification relative to the respective 99th percentiles, as 52.1% of all results with a discordant positive cTnT result had an eGFR Ͼ60 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 , and the results of the McNemar test remained significant (P Ͻ 0.001) for this group.
The details of the outliers detected between the cardiac troponin methods are presented in Table 3 and Fig. 1 . An outlier was detected in 1 patient (0.06%) on the Abbott cTnI platform. The Beckman Coulter cTnI assay had 8 outliers (0.45%), with heterophile antibodies detected in 1 patient as the probable cause of the positive interference. On the Siemens cTnI platform, 3 outliers (0.17%) were present, and in 1 instance heterophile antibodies were detected. On the Roche cTnT platform, 10 samples (0.56%) were classified as outliers, and no heterophile antibody interference was identified with this assay. The hemolytic index did not exceed 1 in any sample in which an outlier was detected. The eGFRs of the cTnT outlier patients were significantly lower than those of the cTnI outlier patients (Student t-test P Ͻ 0.001).
Discussion
In this study, we described and quantified betweenand within-method differences between cTnI assays and between cTnI and cTnT assays. Two aspects in par- ticular that need to be addressed are the variation between methods that cannot be explained by the withinmethod imprecision and the discordant classification of results according to the respective 99th-percentile cutoff thresholds. Although our study is limited by a lack of clinical outcomes data to assist in adjudicating individual discordant results, the large number of samples is representative of the patient population that presents for cardiac troponin testing at our institution. The long-term clinical outcomes as measured by death at 1 year have been reported as similar for the Beckman Coulter and Abbott cTnI assays. Although the Siemens cTnI at a 99th-percentile value of 0.08 g/L was reported as clinically inferior to a research version of the Beckman Coulter assay, there was no significant difference in the area under the curve (AUC) of the ROC analysis (10, 11 ) . The diagnostic performance of the Beckman Coulter and Abbott cTnI assays and the Roche cTnT assays with regard to the diagnosis of MI were also recently reported as similar (12 ) .
The log-linear relationship and good correlation (r Ͼ 0.98) found between the different cTnI methods and the systematic positive bias of the Siemens assay concur with other reports (11, 13 ) . As cTnI and cTnT reflect the same pathological process, the high degree of correlation (r Ͼ 0.89) was expected. The less precise log-linear relationship observed between cTnI and cTnT could be explained by differences in their release and clearance.
Constant and proportional bias between assays can be corrected for, but random variation is more difficult to manage. In this study, we demonstrated that the total observed variances between methods could not be explained by the expected variance from the within-method analytical imprecision of the methods and that the methods therefore cannot be used interchangeably (Table 2 , Fig. 2 ). As expected, the total observed variances between cTnI and cTnT methods were larger than between cTnI methods. By assuming that the weighted means of the variances are representative with small covariance, and by simultaneously solving the 3 sets of cTnI comparisons, we estimated that the method dependent CV was approximately 24%, 12%, and 18% for Abbott, Beckman Coulter, and Siemens assays, respectively. Whereas the observed variation of the differences between cTnI methods was 26%, it was 127% between cTnI and cTnT for all cTnI assays. This difference can probably be explained by the fact that 
Fig. 2. Difference plots illustrating the observed and within-method variance between cardiac troponin assays.
All results were standardized relative to the Abbott cTnI, and differences are expressed as % relative to the mean result. Dashed lines, mean and 95% CI bands of the observed relative differences; red lines, within-method 95% CI bands calculated in bins.
cTnT and cTnI measure different moieties, albeit that they are supposedly released in equimolar amounts via the same pathological process. If we assume that the differences in magnitude of the between-method variation between cTnI assays and those between cTnI and cTnT were due to different analytes measured, it is possible to estimate this analyte-dependent component at 124%. The component reflects the variance between cTnI and cTnT in the blood of patients being investigated for possible MI. Method-dependent variation will contribute significantly to discordant clinical classification, even if results are adjusted for slope and bias, particularly if values are distributed in the vicinity of the cutoff thresholds. The cause of the relatively high methoddependent variance is unknown, but possible factors include: nonidentical antibodies that recognize different epitopes, differences in reagent formulations, hardware, assay parameters, etc. Both the Abbott and Beckman Coulter assays incorporate antibodies targeted against epitopes 24 -40 and 41-49, whereas the Siemens assay includes an additional antibody against epitope 87-91 of the cTnI molecule (10, 11 ) . Factors present in patient serum, such as anti-cardiac troponin antibodies, hemolysis, icterus, lipemia, and drugs may also affect individual assays differently (14 ) .
Defining the decision threshold for cardiac troponin, relative to the 99th-percentile distribution of a reference population, should theoretically identify a similar set of patients irrespective of the assay used. Two factors will contribute to the number of samples discordant using different methods: the betweenmethod variance and the position of the intersection of 99th-percentile decision lines relative to the center of the data distribution. One may reasonably expect the 99th-percentile decision-lines in the comparison graphs to intersect in the center of the data distribution, which would result in a balanced classification with the McNemar test returning a P Ͼ 0.05. Visual inspection shows that this was true only for the Abbott and Beckman Coulter assays ( Fig. 1 and Table 1 ). The respective 99th percentiles of the Roche cTnT and Siemens cTnI assays identified different populations than were identified by the Abbott and Beckman Coulter cTnI assays. The 49% increase in positive results with the cTnT assay according to the published 99th-percentile decision limits may have a clinical impact on patient management and outcome. Because cTnT and cTnI are different analytes, they each have their own biological kinetic characteristics, and it is possible that cTnT is more sensitive to myocardial injury than cTnI and increases earlier or with a lesser amount of cardiac injury.
Without clinical outcomes data, we can only speculate on the clinical implications of this discordant classification. If one assumes that cTnI and cTnT inherently have the same diagnostic specificity and sensitivity, then it is plausible that inconsisten- cies in determining the 99th percentile are responsible for the discordant classification (15, 16 ) . However, a higher diagnostic sensitivity of cTnT for MI would also explain this finding. In the first instance, it would be advantageous to reset the 99th-percentile cutoff thresholds to achieve better concordance, but in the latter case, that may have a deleterious effect on diagnostic specificity. These issues can only be addressed in controlled studies looking at clinical outcomes. In clinical practice, it seems logical to expect concordant patient classification irrespective of the troponin assay used. The percentile decision threshold of cTnI could be lowered or that of cTnT could be increased, but with the consequence of a decrease or increase in the clinical specificity of the particular assay (15 ) . The apparent outliers between methods were identified from the observed variation between methods and were confirmed by visual inspection, with the assumption that the interference would be restricted to 1 assay only. We cannot exclude the possibility that some of the apparent outliers were the result of an interference affecting multiple assays in a similar manner. The interpretation of the cTnT outliers was complicated by the systematic differences between cTnI with respect to the 99th percentile, the large between-method analytical variance, and differences in the release and clearance kinetics. The patients with cTnT outliers had significantly lower renal function than those patients with cTnI outliers, and this may have contributed to their identification as outliers. Despite the obvious differences in the underlying mechanisms the between-method outliers occurred with approximately the same rate on cTnI platforms as the within-method outliers detected by duplicate analysis of samples (betweenmethod outlier rate per patient vs within-method outlier rate per sample: Abbott 0.06% vs 0.10%; Beckman Coulter 0.28% vs 0.44%; Siemens 0.11% vs 0.10%) (6, 17 ) . The outlier rate between methods of 0.68% with the Roche cTnT assay was higher than the 0.06% within-method outlier rate.
The general agreement in z values between subsequent samples was suggestive of a patient-specific interference such as an interfering antibody in patients B1, B2, R5, and R6 (Table 3 ). In patients R8 and R10, the changes in z values of serial samples were suggestive of a sample-specific interference or a time-dependent kinetic difference. Heterophile antibodies as a possible cause of a falsely increased cTnI were detected in 2 individuals with the Beckman Coulter and Siemens cTnI assays. It is worth noting that heterophile antibodies occurred at a rate 8 times lower than the between-method outliers and approximately 10 times lower than within-method outliers on the Beckman Coulter platform. The underlying cause of the rest of the outliers is speculative, but hemolysis as a contributing cause was excluded. A high prevalence (15.9%) of anti-troponin I and T antibodies has been reported previously, and it was postulated that these antibodies may potentially cause both positive and negative interference with clinical samples (18 ) . Our results demonstrated negative interference in 1 case with the Abbott cTnI assay. Even if all the apparent outliers detected in this study, excluding those that were accounted for by heterophile antibodies, were assumed to be the consequence of autoantibodies (20/1773 or 1.1% of the study population), it would be considerably less than the reported 15.9%.
It is known that cTnT is affected by impaired renal function, and we investigated the contribution of renal function on the relationship between cTnI and cTnT in Fig. 3 . In the subgroup with normal renal function (eGFR Ͼ60 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 ), 187 samples had a discordantly positive cTnT compared to 8 samples with a discordantly positive Abbott cTnI (McNemar P Ͻ 0.001). We therefore concluded that although impaired renal Cardiac Troponin I and T Comparison function increased cTnT relative to cTnI in an inverse manner, it could not explain the increase in discordantly positive cTnT results.
The diagnosis of MI should be independent of the choice of analyte or analyzer. The diagnostic industry is currently focused on improving the analytical imprecision and sensitivity to meet the performance guideline of a maximum 10% CV at the 99th percentile. Although none of the cTnI assays in this study met this performance goal (6 ), the analytical imprecision was overshadowed by the betweenmethod variation, and it is questionable whether future improvement of analytical imprecision alone will alter this scenario. Attempts at standardization and harmonization of cTnI assays to improve commutability have been unsuccessful to date, and our data demonstrate that adjustment of slopes and intercepts will be futile unless the root cause of the between-method variation is addressed. The variation between cTnI and cTnT was greater than between cTnI methods, with analyte-dependent variance (cTnI vs cTnT) being the major contributor. The latter variance is innate and probably impossible to improve. The discordant classification of subjects relative to the 99th percentile cutoff of the different assays cannot be explained by a lack of standardization, as these decision thresholds are assay specific. The discordant classification at the 99th percentile may reflect differences in the reference populations used to establish these cutoffs, or by a different relationship between the results of a reference population and a population with myocardial damage, especially for cTnI and cTnT. If this proves to be the case, the only way to "balance" the diagnostic power of cTnI and cTnT assays would be to have cutoff thresholds based on different percentiles of a reference population.
We have quantified the correlation and variance between 4 contemporary cardiac troponin assays. Method-dependent as well as analyte-dependent factors have been identified as major contributors to this variance, and our data provide baseline statistics to assess success of endeavors to harmonize cardiac troponin assays. The effect of these issues on the universal applicability of cardiac troponin testing and its clinical implication is uncertain, and therefore it is also unclear what the quality goals should be. 
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